KODIAK SCIENCES INC. Amortization of Debt Issuance Costs and Discounts
KODIAK SCIENCES INC. (KOD) reported Amortization of Debt Issuance Costs and Discounts of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2021-03-01
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for fiscal 2020 was $0.00.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for fiscal 2018 was $5.48M, a 372.18% increase from fiscal 2017.
- KODIAK SCIENCES INC. amortization of debt issuance costs and discounts for fiscal 2017 was $1.16M.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | $187.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | $187.00K derived: sum of 3 quarters · filed 2021-03-01 | $2.15M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | $187.00K derived: sum of 2 quarters · filed 2021-03-01 | $2.15M derived: sum of 3 quarters · filed 2021-03-01 | $4.02M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.15M derived: sum of 2 quarters · filed 2021-03-01 | $4.02M derived: sum of 3 quarters · filed 2021-03-01 | $5.48M 10-K · filed 2021-03-01 |
| 2018-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.83M derived: sum of 2 quarters · filed 2019-11-12 | $5.29M 10-Q · filed 2019-11-12 | $6.06M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $3.33M 10-Q · filed 2019-08-14 | $4.10M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | $1.46M 10-Q · filed 2019-05-15 | $2.23M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | $769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.16M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | $392.00K 10-Q · filed 2018-11-16 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |